Shingles in Alberta: Before and after publicly funded varicella vaccination  by Russell, Margaret L. et al.
S
v
M
L
a
b
a
A
R
R
A
A
K
H
H
P
A
1
l
M
v
i
i
m
n
o
o
2
(
l
0
hVaccine 32 (2014) 6319–6324
Contents lists available at ScienceDirect
Vaccine
j our na l ho me page: www.elsev ier .com/ locate /vacc ine
hingles  in  Alberta:  Before  and  after  publicly  funded
aricella  vaccination
argaret  L.  Russell a,∗, Douglas  C.  Doverb, Kimberley  A.  Simmondsb,
awrence  W.  Svensonb
Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada T2N 4Z6
Epidemiology and Surveillance Team, Alberta Ministry of Health, 23rd ﬂoor Telus Plaza NT 10025 Jasper Avenue, Edmonton, Alberta, Canada AB T5J 1S6
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 24 May  2013
eceived in revised form 28 August 2013
ccepted 10 September 2013
vailable online 4 October 2013
eywords:
erpes zoster/epidemiology
erpes zoster/prevention and control
opulation surveillance
lberta/epidemiology
a  b  s  t  r  a  c  t
Purpose:  A  universal  publicly  funded  chickenpox  vaccination  program  was  implemented  in  Alberta  in
2002. We  examine  the  epidemiology  of  medically  attended  shingles  in Alberta  from  1994 to 2010.
Methods:  Incident  shingles  cases  (earliest  health  service  utilizations  for ICD-9  053  or  ICD-10-CA  B02)
and  their  co-morbid  conditions  for the  12  months  prior  to  shingles  diagnosis  were  identiﬁed  from  the
records  of  Alberta’s  universal,  publicly  funded  health-care  insurance  system  for  1994–2010.  Shingles
diagnostic  codes  at least  180  days  after  the  ﬁrst were  classiﬁed  as recurrent  episodes.  Denominators  for
rates  were  estimated  using  mid-year  population  estimates  from  the Alberta  Health  Care  Insurance  Plan
Registry.  Annual  age-  and sex-speciﬁc  rates  were  estimated.  We  estimated  the  proportion  of all  cases
that were hospitalized.  We  explored  the  pattern  of rates  for  sex,  age-group  co-morbidity  and  year  effects
and  their  interactions.
Results:  Crude  rates  of shingles  increased  over  the  interval  1994–2010.  Most  persons  had  only  a  single
episode  of shingles;  4%  of  cases  were  hospitalized.  Shingles  rates  were  higher  among  females  than  males.
While  only  2%  of shingles  cases  had  one  or  more  co-morbidities,  this  proportion  was  also  higher  for
females  than  males.  Prior  to 2002,  all age  groups  of both  sexes  experienced  increasing  annual  rates  of
shingles.  However,  there  was  a sharp  decline  in  the rate  of shingles  for  both  females  and  males  under  the
age of  10  years  for  2002–2010,  the period  in  which  there  was  publicly  funded  chickenpox  vaccination.
Conclusion:  The  declining  rates  of shingles  among  persons  under  the  age  of  10  years are  consistent
with  an impact  of  the  chickenpox  vaccination  program.  The  trend  of increasing  rates  of shingles  among
older  persons  began  prior  to  implementation  of vaccination.. Background
Herpes zoster (shingles) results when there is reactivation of
atent varicella zoster virus after a primary episode of chickenpox.
odelling studies have suggested that the introduction of mass
accination programs against varicella might, over time, lead to an
ncrease in rates of herpes zoster (shingles) [1] because of a lack of
mmunological boosting due to exposure to varicella virus. Changes
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in shingles epidemiology might be apparent within 10 years of
implementation of a varicella (chickenpox) vaccination program
[1–5].
Varicella vaccines were licensed in Canada in 1998 but ini-
tially were not publicly funded in any province or territory. Alberta
became the second Canadian province (after Prince Edward Island)
to introduce a publicly funded varicella vaccination program. The
publicly funded Alberta program targeted special groups (e.g.,
healthcare workers and children in grade 5 who did not have a
prior history of chickenpox, shingles or chickenpox vaccination)
beginning in spring 2001 [6]. Starting in July 2001, a single dose of
chickenpox vaccine was added to the routine immunization sched-
ule for all children one year of age (i.e., administered at age 12
months); in spring 2002 a single dose of chickenpox vaccine was
also offered to all pre-schoolers born on or after January 1, 1997
(catch-up). The routine vaccination schedule for infants in Alberta
has thus included a single dose of chickenpox vaccine to be given
at age 12 months since 2001 and the programme gave rise to a
dramatic increase in vaccine uptake. Chickenpox vaccine coverage
reserved.
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Table 1
Co-morbidities of interest by databases used to identify them.
Condition Databases used
HIV/AIDS CDRS
Neoplasms including in situ,
those of uncertain or
unknown behaviour, and all
malignant neoplasms
excluding non-melanoma
skin cancers
Alberta cancer registry
Agranulocytosis (ICD-9-CM
284.0–284.9, 288.0–288.2 or
ICD-10-CA D70)
SESE, MACAR (hospital morbidity
inpatient database)
Immune system disorders
(ICD-9-CM 279.0–279.9 or
ICD-10-CA D80-89)
SESE, MACAR (hospital morbidity
inpatient database)320 M.L. Russell et al. / Va
as less than 5% in 2001, the last year in which vaccine was  avail-
ble only by private purchase. It jumped to 60% in 2002 (ﬁrst
ear of publicly funded vaccine for routine childhood vaccination
chedule). In 2005 and in every subsequent year, it exceeded 80%
Alberta Health, unpublished data). Alberta introduced a second
ose of chickenpox vaccine for children aged 4–6 years into the
outine childhood vaccination schedule in August 2012 [7]. It has
een shown that publicly funded varicella immunization programs
n Canada and the United States have resulted in a reduction in
hickenpox incidence [5,6,8]. However, the impact of these pro-
rammes on shingles is less clear because the incidence of shingles
egan to increase before chickenpox vaccination programs were
ntroduced [9,10]; thus programme evaluations that do not con-
ider this may  result in misleading interpretations of the observed
ata. It is now more than 10 years since the implementation of
he Alberta publicly funded chickenpox vaccination program. We
xamine the epidemiology of shingles in Alberta over 1994–2010.
hese data span the pre-vaccine era (1994–1998), the period in
hich vaccine was licensed in Canada but not publicly funded in
lberta – i.e., ‘private availability’ (1999–2001), and the time since
mplementation of the publicly funded varicella vaccination pro-
ram (2002–2010 – ‘public availability’).
. Methods
Alberta has a universal publicly funded health care insurance
ystem. Over 99% of Albertans are covered by this programme
nd the registration ﬁle for this programme includes demographic
nformation about registrants as well as a unique personal identiﬁer
hat can be used to link the registration ﬁle to other adminis-
rative health databases [9]. Medically attended shingles cases
ere identiﬁed over the interval 1994–2010 for each calendar
ear using data from physician visits and hospital admissions. The
atabases employed included the Supplemental enhanced service
vent system (SESE – physician claims) [6], the Alberta commu-
icable disease reporting system (CDRS), and the morbidity and
mbulatory care reporting (MACAR) databases held by the Alberta
inistry of Health. MACAR includes data from both hospital inpa-
ients (hospital morbidity inpatient database) and from hospital
mergency department visits and outpatient procedures. The ﬁrst
ated health service utilization for ICD-9-CM code of 053 or ICD-
0-CA code of B02 was classiﬁed as incident. Diagnostic codes at
east 180 days after the ﬁrst were classiﬁed as recurrent episodes.
or each year, we estimated the proportion of cases that had one
r more of selected co-morbidities (thought most likely to be
elated to immunosuppression from condition or treatment for the
ondition) in the 12 months prior to the incident shingles diag-
osis. Co-morbidities were identiﬁed using linkage by personal
ealth number to multiple chronic disease databases (Table 1).
enominators for rates were estimated using mid-year population
stimates from the Alberta Health Care Insurance Plan Registry [11]
hich have been shown to be a reliable population data source
12]. Annual age- and sex-speciﬁc rates were estimated. We  esti-
ated the proportion of all cases that were hospitalized and that
ad co-morbidities by age-group for each year and sex. Shingles
ates were modelled with a Poisson model. Denominators for the
odelled rates used the mid-year population estimates linking
ndividuals to co-morbidity status determined by any of the listed
o-morbidities during that calendar year. We  explored the pattern
f rates for sex, age, co-morbidity and year effects and their inter-
ctions. Of a priori interest were the three time periods related to
aricella vaccine accessibility in Alberta. In the pre-licensure period
1994–1998) vaccine was not available in Canada. During the pri-
ate availability (1999–2001) period, vaccine was available but not
ublicly funded, thus available only to persons who  had to pay.Cystic ﬁbrosis ICD-9-CM 277.0,
ICD-10-CA-E84)
SESE, MACAR (hospital morbidity
inpatient database)
In the public availability period (2002–2010), vaccine was publicly
funded. The independent variables in the Poisson model included:
linear trends within each time period (1994–1998, 1999–2001,
2002–2010), sex, age-group (<10 years, 10–44 years, 45–64 years,
65 years or older), co-morbidity status (any vs. none) and two-
way interaction terms (age-group × sex, age-group × co-morbidity,
time-period × age-group, time-period × sex, sex × co-morbidity).
An alpha level of 0.05 was used to test for signiﬁcance of interaction
terms. As the two-way interactions for co-morbidity × age-group
and for co-morbidity × sex were signiﬁcant at 0.05, a three way
interaction term (age-group × sex × co-morbidity) was  added to
the model. The goodness of ﬁt statistic (deviance goodness of ﬁt
1.6) indicated this was an appropriate model. There was no dif-
ference between the pre-licensure and private availability period,
so these periods were pooled for the ﬁnal model without affecting
model ﬁt. In sensitivity analysis, we  modelled only ﬁrst episodes of
shingles to determine the impact of modelling numbers of episodes
rather than numbers of individual persons. Secular trends are
described using locally weighted scatter plot smoothing (LOESS)
curves [13]. SAS 9.2 (SAS Institute Inc, Cary, NC) was  used for all data
manipulation and analysis, except the LOESS which was  carried out
using SigmaPlot 11.0 (Systat Software, San Jose, CA).
2.1. Ethics
The study was  approved by the Conjoint Health Research Ethics
Board of the University of Calgary (E 23776, E17522).
3. Results
Fig. 1 shows that crude rates of medically attended shingles
episodes increased over the interval 1994–2010. The crude rate for
1994 was 3.5 per 1000 person-years. This increased to 3.8/1000
person-years in 1998, to 4.0/1000 person-years by 2001 and to
4.5/1000 person-years by 2010.
Most patients (90%) had only a single episode of shingles; 8%
had 2 episodes and 2% had more than 2 episodes (data not shown).
As can be seen in Table 2, for the overall interval 1994–2010, 59%
of medically attended shingles episodes (cases) occurred among
females. Rates were higher among females than males over the
entire interval, and increased more rapidly for females than males
(Fig. 2).
Less than 2% of shingles cases had one or more co-morbidities
in the 12 months prior to shingles diagnosis and this proportion
remained stable throughout all three periods studied (Table 2).
A slightly higher proportion of female than male cases had a co-
morbidity and this pattern was  also stable over all three periods
studied (data not shown).
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Fig. 1. Crude rates of medically attended shingles per 1000 population (with 95%
conﬁdence intervals and LOESS ﬁt curve), 1994–2010.
Fig. 2. Sex-speciﬁc medically attended shingles rates per 1000 population (with
95% conﬁdence intervals and LOESS ﬁt curves), 1994–2010.
Table 2
Characteristics of medically attended shingles episodes by attribute and time period of in
Attribute Time period
Pre-licensure
1994–1998
Priv
199
Gender
Female: n, (%) 29,050 (58.1) 20,6
Male: n, (%) 20,977 (41.9) 14,5
Age  group
<10 years: n, (%) 4295 (8.6) 272
10–44  years: n, (%) 19,719 (39.4) 13,5
45–64  years: n, (%) 12,874 (25.7) 990
65+  years: n, (%) 13,139 (26.3) 908
Total  number of shingles episodes 50,027 35,2
Hospitalized: n, (%) 2562 (5.1) 153
Co-morbid health conditionsa: n, (%) 835 (1.7) 619
Average number of Episodes per Year 10,005 11,7
N  persons with 1 episode 
N  persons with
2 episodes 
N  persons with >2 episodes 
Total N persons with 1 or more episodes 
Average Alberta population 2,758,141 2,97
a One or more co-morbid health conditions in the 12 months prior to shingles diagnosiFig. 3. Age-speciﬁc medically attended shingles rates, per 1000 population, and
availability of chickenpox vaccine: 1994–98 (pre-licensure), 1999–2001 (private
availability), 2002–2010 (public availability).
Only 4% of shingles cases were hospitalized over the interval
1994–2010; however this proportion declined over the 3 periods
of varicella vaccine availability from 5.1% to 3.4% (Table 2).
The age-speciﬁc rates begin to sharply increase for all of the
older age groups starting with the age group of 45–49 years in all
3 periods of interest (Fig. 3). In contrast, however, among children
aged less than 10 years, the rates of medically attended shingles
were much lower for the publicly available period of 2002–2010
than for either the years when vaccine was  only available by private
purchase (1999–2001) or those of the pre-vaccine (1994–1998)
period.
3.1. Poisson modelTables 3 and 4 display results from this Poisson model. The
effect of co-morbidities is much more pronounced in the younger
age groups than in the older age groups (Table 3). For males aged
terest, Alberta 1994–2010.
ate availability
9–2001
Public availability
2002–2010
Overall
1994–2010
82 (58.6) 76,210 (59.6) 125,942 (59.1)
90 (41.4) 51,756 (40.5) 87,323 (41.0)
9 (7.7) 4880 (3.8) 11,904 (5.6)
50 (38.4) 45,851 (35.8) 79,120 (37.1)
7 (28.1) 43,045 (33.6) 65,826 (30.9)
6 (25.8) 34,190 (26.7) 56,415 (26.5)
72 127,966 213,265
2 (4.3) 4385 (3.4) 8479 (4.0)
 (1.8) 2240 (1.8) 3694 (1.7)
57 14,218 12,545
174,711
15,909
3964
1,94,584
0,637 3,350,524 3,109,255
s.
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Table 3
Poisson model results: impact of co-morbidities on medically attended shingles rates by sex and age-group.
Sex Age-group Co-morbidities RRa (95% conﬁdence interval) Within sex–age-group RRb (95% conﬁdence interval)
Females <10 years Yes 0.63 (0.44, 0.90) 2.57 (1.81, 3.66)
No  0.25 (0.23, 0.26)
10–44 years Yes 0.64 (0.58, 0.70) 1.96 (1.79, 2.15)
No  0.33 (0.31, 0.34)
45–64 years Yes 1.01 (0.93, 1.09) 1.60 (1.49, 1.72)
No 0.63 (0.60, 0.66)
65 years or older Yes 1.07 (1.00, 1.15) 0.93 (0.88, 1.00)
No 1.15 (1.05, 1.27)
Males <10 years Yes 0.59 (0.42, 0.83) 2.70 (1.92, 3.80)
No 0.22 (0.21, 0.23)
10–44 years Yes 0.90 (0.79, 1.03) 3.63 (3.19, 4.13)
No  0.25 (0.24, 0.26)
45–64 years Yes 0.66 (0.60, 0.73) 1.56 (1.42, 1.72)
No  0.43 (0.41, 0.44)
65 years or older Yes 0.93 (0.87, 1.00) 0.93 (0.87, 1.00)
No 1.00 (Reference group)
a RR, relative risk of shingles compared to males aged 65 years or older with no co-morbidities.
b Reference group: persons with no co-morbidities within same age-sex stratum.
Table 4
Annual percent change in medically attended shingles rates by age and sex by period.
Sex Age-group Period P-value (2-tailed) for
difference across periods
1994–2001 (Combined pre-licensure and
private availability periods)
2002–2010 (Public available period)
Within age–sex group annual percent change
(95% conﬁdence interval)
Within age–sex group annual percent change
(95% conﬁdence interval)
Females <10 years 1.2 (0.3, 2.2) −10.1, (−10.8, −9.4) <0.0001
10–44 years 1.7 (1.2, 2.1) 1.5 (1.2, 1.8) 0.7443
45–64 years 2.1 (1.6, 2.6) 1.7 (1.4, 2.0) 0.2666
65  years or older 1.4 (0.8, 1.9) 0.5 (−0.3, 1.2) 0.0203
Males <10 years 0.2 (-0.7, 1.2) −10.2 (−11.0%, −9.5) <0.0001
10–44 years 0.6 (0.2, 1.1) 1.4 (1.1, 1.7) 0.0398
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i45–64 years 1.1 (0.6, 1.7) 
65  years or older 0.4 (−0.2, 0.9) 
10 years, the relative risk of shingles is 2.6 times higher for
hose with co-morbidities than for those without; this relative risk
eclines to 0.93 for the 65+ age group. There is a notably sharp
ecline in the rate of shingles for both females and males under the
ge of 10 years (Table 4). The annual percentage change of minus
0% represents an annual decrease in the shingles rate starting in
nd persisting through the public availability period (2002–2010).
rior to this, all age groups had similar trends with slightly increas-
ng rates, though females had higher annual percentage changes. A
ensitivity analysis that included only ﬁrst episodes did not change
stimated parameters.
. Discussion
This paper expands the data available on secular trends in shin-
les incidence by providing additional data from outside the United
tates. It thus captures data from a population for whom health
are and chickenpox vaccination is universally publicly funded and
hich differs demographically from that of the United States [14].
ur study is population based and we used data from Alberta’s
niversal publicly funded healthcare system in our analyses. Thus
election bias due to direct ﬁnancial costs for health services does
ot affect our ﬁndings. We  also have data for both the pre-vaccine
ra and for a longer period after public funding of chickenpox vac-
ine than for other reports from Canada [15].In prior work, we described the epidemiology of medically
ttended shingles in Alberta between 1986 and 2002 [9]. As in our
rior report, we ﬁnd a continuing trend of increase in crude med-
cally attended shingles rates that began in the pre-vaccine era.1.6 (1.2, 1.9) 0.2678
1.1 (0.8, 1.5) 0.0686
Concerns have been raised that chickenpox vaccination programs
might lead to a decrease in the hypothesized ‘immune boosting’
effect of exposure to wild virus [2]. One might thus anticipate that
there would be an increase in shingles rates in the age groups repre-
senting older unvaccinated cohorts [3]. This pattern while present
in the publicly available period was  also present prior to vaccine
licensure. We  do not think that this trend would be explained by
an increase in health service utilization over the period because the
age-speciﬁc rates of health service utilization for both males and
females in Alberta have been stable until 2010 when a decline was
observed for all age groups of both sexes (Alberta Health, unpub-
lished).
We  also observed a continuing trend of higher rates among
females than males for all age-groups over the age of 9 years.
Although the validity of diagnostic codes for shingles was slightly
lower for females than for males in an American study, shingles was
still more common in females than in males [16]. The higher rates of
medically attended shingles in females than males might be related
to gender differences in immunosuppressive disease or therapies
[17]; we were not able to examine this. One may  also speculate that
there might be gender differences in immune responses to latent
viral infections. Gender differences in health seeking behaviour
could also contribute to the observed higher rate of shingles in
females than males; for persons aged less than 65 years, rates of
health service utilization are higher for females than for males in
Alberta (Alberta Health, unpublished).
Among the youngest age-group (i.e., less than 10 years of age),
medically attended shingles rates have declined in the post-vaccine
era for both females and males. This is not surprising as this is the
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ge-group that would have received chickenpox vaccine, and the
ate of shingles among those immunized is lower than among per-
ons who have had wild disease [18]. The data used for the analysis
ere assembled and analyzed at the individual level prior to aggre-
ations being created. Although we used individual level data to
stimate shingles rates, we did not have individual level data to
ssess chickenpox vaccination. Therefore, it is possible that some
actor other than the introduction of the publicly funded chick-
npox vaccination program might be responsible for part of the
bserved changes in shingles rates over the periods of examined.
hus our ﬁndings may  be prone to the ‘ecologic fallacy’ where the
esults from aggregate data may  not fully apply at the individual
evel [19]. We  did not attempt to generalize overall trends within
ny age/sex group to the individual level. Other possible explana-
ions for the increasing rates of shingles among older persons over
ime include possible secular trends (increases) in the occurrence
f immunosuppressive diseases or therapies [17,20].
Having a co-morbid health condition was strongly associated
ith medically attended shingles rates for both sexes among per-
ons aged less than 65 years. Although the proportion of medically
ttended shingles cases with a co-morbid condition in the 12
onths prior to medically attended shingles episode is less than
%, this proportion may  be increasing among females compared to
ales in the public availability period for shingles vaccine.
Although we found that only 4% of medically attended shingles
ases were hospitalized, this is an over-estimation of the proportion
f cases where the hospitalization is attributable to shingles. It has
een observed elsewhere that two-thirds of hospitalizations that
ncluded zoster codes in any position of a permitted15 diagnostic
odes for hospitalization were incidental to the hospitalization[21].
n our study, 90% of medically attended shingles episodes were
lassiﬁed as incident and 10% as recurrent. This is likely an over-
stimation of the proportion of episodes that are recurrent. A study
hat validated diagnoses and which included a 12 year follow-up,
ound that recurrence occurs in about 6% of cases [16]. Some of the
pisodes that we classiﬁed as recurrent may  have been misclassi-
ed despite our requirement of a minimum of 180 days between
isits in our case deﬁnition of recurrence. Misclassiﬁcation could
lso have occurred due to coding errors for a different true diag-
osis or because a herpes zoster code was used for a situation in
hich the clinician had indicated only a past history of disease.
his has been observed elsewhere [16]. We  were not able to vali-
ate the shingles diagnostic codes used in this study. A comparison
f administrative data to medical records in the United States found
hat using administrative data alone resulted in a zoster occurrence
ate that was inﬂated by 17.4% (95% CI 15.4, 19.5) and an absolute
ifference in incidence of 0.78/1000 person years [16]. However,
e used similar methods to ascertain cases in both the pre- and
ost-vaccine eras and do not anticipate that it would affect the pat-
erns observed. We  acknowledge that we may  have over-estimated
hingles rates among children as it has also been shown that the
alidity of a shingles diagnosis from administrative data varies by
ge and is lower among younger than older persons; particularly
or younger children [17]. We  perceive that one of the impacts of
ffective chickenpox vaccination programs will be that clinicians
ay  become more likely to misdiagnose both chickenpox and shin-
les over time in younger persons; the implementation of shingles
accination programs may  have a similar impact among older per-
ons. Thus it is increasingly important that validation studies of
dministrative data be done on an ongoing basis and further, as
iseases become less common the use of more highly speciﬁc case
eﬁnitions will be important.
Our study did not capture cases of shingles that did not seek
edical care; we are not able to estimate this proportion but it
s possible that this proportion might have decreased over time if
ublic awareness of treatments for shingles has changed over time.
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The risk factors responsible for the overall trend of increas-
ing shingles rates that began prior to chickenpox vaccination are
not understood, although changes in age and immune status of
populations are thought to be inadequate to explain them [18].
Ongoing surveillance of both chickenpox and shingles are essential,
but other factors make epidemiologic interpretation increasingly
complex, including dosing schedules for chickenpox and shingles
vaccines, population mixing patterns by age group and sex, and
possible changes in the virus itself. Alberta introduced a second
dose of chickenpox vaccine into the routine childhood vaccina-
tion schedule in August 2012 [7]. Live attenuated shingles vaccine
was approved in Canada in August 2008 [22], is licensed for per-
sons aged 50 years or older and recommended for persons without
contraindications aged 60 years or older as of 2010 [22]. Although
not as yet publicly funded in Alberta it is available for private pur-
chase; we were not able to consider utilization of shingles vaccine
in our analyses. However, one would anticipate that a high uptake
of this vaccine would be expected to reduce shingles rates among
the population targeted for vaccination. Ongoing surveillance of
chickenpox and shingles vaccine coverage is critically important.
5. Conclusion
Eight years after the implementation of a routine publicly
funded childhood chickenpox vaccination program in Alberta,
there is a sharp decline in the rate of medically attended shingles
for both females and males under the age of 10 years. Rates of med-
ically attended shingles among older persons continue to increase
and are higher for females than males; but it is not possible to assess
the contribution of the vaccination program to this phenomenon as
this is a continuation of a trend observed prior to vaccine licensure.
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